Advertisement

Insights into the c-Jun N-terminal kinase 3 (JNK3) inhibitors: CoMFA, CoMSIA analyses and molecular docking studies

  • Yanda Liu
  • Yewei Xie
  • Yuanyuan Liu
  • Pengcheng Wang
  • Jiaxi Ye
  • Yalun Su
  • Zhihong Liang
  • Zhaohui He
  • Haibo Zhou
  • Guochao Liao
  • Jun Xu
  • Yiqun ChangEmail author
  • Pinghua SunEmail author
Original Research
  • 10 Downloads

Abstract

JNK3, a protein kinase of the MAPK family that is potently activated by a variety of environmental stress and pro-inflammatory cytokines, has been recognized as an important therapeutic target for several neurodegenerative diseases. However, due to the long development cycle and the cost of R&D, no related drugs have been released. By applying the CoMFA and CoMSIA methods, QSAR models that explore the structure-activity relationship of the JNK3 inhibitors are established and validated, the parameters are satisfactory (q2 = 0.774, r2 = 0.991 for CoMFA model and q2 = 0.666, r2 = 0.990 for CoMSIA model) and base on which a series of novel molecules are designed. Molecular docking is conducted to verify the potential of the new compounds, the results shows promising activity. We speculated that the series of compounds S1S11 might have some therapeutic activity in the c-jnk3 pathway, particularly the “S8” may prove to be the best one, which provided useful guidance for the design of new and efficient subtype selective JNK3 inhibitors.

Keywords

JNK3 Potential inhibitory activity QSAR Molecular docking 

Notes

Acknowledgements

This work was supported by the Natural Science Foundation of China (No. 81573294, 81773593, 81872759), the Excellent Young Teachers Program of Guangdong Provincial Colleges and Universities (YQ 2015061) and the Pearl River S&T Nova Program of Guangzhou (201610010100). We thank the software support from Dr. Junxia Zheng of the Guangdong University of Technology.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Ansideri F, Macedo JT, Eitel M, El-Gokha A, Zinad DS, Scarpellini C, Laufer SA (2018) Structural Optimization of a Pyridinylimidazole scaffold: shifting the selectivity from p38α mitogen-activated protein kinase to c-Jun N-terminal kinase 3. ACS Omega 3(7):7809–7831CrossRefGoogle Scholar
  2. Buckingham J, Glen RC, Hill AP, Hyde RM, Martin GR, Robertson AD, Woollard PM (1995) Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties. J Med Chem 38(18):3566–3580CrossRefGoogle Scholar
  3. Cervigni RI, Bonavita R, Barretta ML, Spano D, Ayala I, Nakamura N, Colanzi A (2015) JNK2 controls fragmentation of the Golgi complex and the G2/M transition through phosphorylation of GRASP65. J Cell Sci 128(12):2249–2260CrossRefGoogle Scholar
  4. Chambers JW, Howard S, LoGrasso PV (2013) Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced toxicity in vitro and in vivo. J Biol Chem 288(2):1079–1087CrossRefGoogle Scholar
  5. Chambers JW, Pachori A, Howard S, Ganno M, Hansen Jr D, Kamenecka T, Cherry L (2011) Small molecule c-jun-N-terminal kinase inhibitors protect dopaminergic neurons in a model of Parkinson’s disease. Acs Chem Neurosci 2(4):198–206CrossRefGoogle Scholar
  6. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Davis RJ (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76(6):1025–1037CrossRefGoogle Scholar
  7. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, Schleif WA (1994) L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 37(21):3443–3451CrossRefGoogle Scholar
  8. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ (1996) Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15(11):2760–2770CrossRefGoogle Scholar
  9. Gutierrez GJ, Tsuji T, Chen M, Jiang W, Ze’ev AR (2010) Interplay between Cdh1 and JNK activity during the cell cycle. Nat Cell Biol 12(7):686CrossRefGoogle Scholar
  10. Hibi M, Lin ANNING, Smeal T, Minden A, Karin M (1993) Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Gene dev 7(11):2135–2148CrossRefGoogle Scholar
  11. Huang X, Liu T, Gu J, Luo X, Ji R, Cao Y, Jiang H (2001) 3D-QSAR model of flavonoids binding at benzodiazepine site in GABAA receptors. J Med Chem 44(12):1883–1891CrossRefGoogle Scholar
  12. Jain AN (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46(4):499–511CrossRefGoogle Scholar
  13. Kamenecka T, Jiang R, Song X, Duckett D, Chen W, Ling YY, Cameron MD (2009) Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. J Med Chem 53(1):419–431CrossRefGoogle Scholar
  14. Klebe G, Abraham U (1999) Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. J Comput Aid Mol Des 13(1):1–10CrossRefGoogle Scholar
  15. Koch P, Gehringer M, Laufer SA (2014) Inhibitors of c-Jun N-terminal kinases: an update. J Med Chem 58(1):72–95CrossRefGoogle Scholar
  16. Krenitsky VP, Nadolny L, Delgado M, Ayala L, Clareen SS, Hilgraf R, Wright J (2012) Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 22(3):1433–1438CrossRefGoogle Scholar
  17. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Woodgett JR (1994) The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369(6476):156CrossRefGoogle Scholar
  18. Lange A, Günther M, Büttner FM, Zimmermann MO, Heidrich J, Hennig S, Koch P (2015) Targeting the gatekeeper MET146 of C-Jun N-terminal kinase 3 induces a bivalent halogen/chalcogen bond. J Am Chem Soc 137(46):14640–14652CrossRefGoogle Scholar
  19. Li S, Fan J, Peng C, Chang Y, Guo L, Hou J, Xiao G (2017) New molecular insights into the tyrosyl-tRNA synthase inhibitors: CoMFA, CoMSIA analyses and molecular docking studies. Sci Rep 7(1):11525CrossRefGoogle Scholar
  20. Mishra P, Günther S (2018) New insights into the structural dynamics of the kinase JNK3. Sci Rep 8(1):9435CrossRefGoogle Scholar
  21. Mohit AA, Martin JH, Miller CA (1995) p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron 14(1):67–78CrossRefGoogle Scholar
  22. Muth F, El-Gokha A, Ansideri F, Eitel M, Döring E, Sievers-Engler A, Laufer SA (2017) Tri-and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3. J Med Chem 60(2):594–607CrossRefGoogle Scholar
  23. Qin LT, Liu SS, Xiao QF, Wu QS (2013) Internal and external validtions of QSAR model: Review. Environ Chem 32(7):1205–1211Google Scholar
  24. Rech JC, Yato M, Duckett D, Ember B, LoGrasso PV, Bergman RG, Ellman JA (2007) Synthesis of potent bicyclic bisarylimidazole c-jun N-terminal kinase inhibitors by catalytic C−H bond activation. J Am Chem Soc 129(3):490–491CrossRefGoogle Scholar
  25. Schattel V, Hinselmann G, Jahn A, Zell A, Laufer S (2011) Modeling and benchmark data set for the inhibition of c-Jun N-terminal kinase-3. J Chem Inf Model 51(3):670–679CrossRefGoogle Scholar
  26. Sharma P, Ghoshal N (2006) Exploration of a binding mode of benzothiazol-2-yl acetonitrile pyrimidine core based derivatives as potent c-Jun N-terminal kinase-3 inhibitors and 3D-QSAR analyses. J Chem Inf Model 46(4):1763–1774CrossRefGoogle Scholar
  27. Siddiqui MA, Reddy PA (2010) Small molecule JNK (c-Jun N-terminal kinase) inhibitors. J Med Chem 53(8):3005–3012CrossRefGoogle Scholar
  28. Srivastava V, Kumar A, Mishra BN, Siddiqi MI (2008) Molecular docking studies on DMDP derivatives as human DHFR inhibitors. Bioinformation 3(4):180CrossRefGoogle Scholar
  29. Wang Z, Chang Y, Han Y, Liu K, Hou J, Dai C, Chen W (2016) 3D-QSAR and docking studies on 1-hydroxypyridin-2-one compounds as mutant isocitrate dehydrogenase 1 inhibitors. J Mol Struct 1123:335–343CrossRefGoogle Scholar
  30. Xiao A, Zhang Z, An L, Xiang Y (2008) 3D-QSAR and docking studies of 3-arylquinazolinethione derivatives as selective estrogen receptor modulators. J Mol Model 14(2):149–159CrossRefGoogle Scholar
  31. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Pederson T (2006) Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. J Med Chem 49(15):4455–4458CrossRefGoogle Scholar
  32. Zheng K, Iqbal S, Hernandez P, Park H, LoGrasso PV, Feng Y (2014) Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. J Med Chem 57(23):10013–10030CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of PharmacyJinan UniversityGuangzhouP. R. China
  2. 2.International Institute for Translational Chinese MedicineGuangzhou University of Chinese MedicineGuangzhouChina
  3. 3.International Research Center of Medicinal AdministrationPeking UniversityBeijingP. R. China
  4. 4.Faculty of Medicine and Healththe University of SydneySydneyAustralia

Personalised recommendations